Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addiction therapies, announced the filing of a new U.S. utility patent application for its lead investigational treatment AD04 targeting Alcohol Use Disorder. The expedited patent filing could secure protection through at least 2045, strengthening the company's intellectua…